ST. MARYS, W. Va.--(BUSINESS WIRE)--ProtoKinetix, Incorporated (OTC:PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) today announces that it has completed the first year of retinal replacement therapy trials on animals and the results are encouraging enough to proceed to a second phase of testing.
There are several diseases that, over time, destroy retinal cells ultimately causing blindness. These diseases include Age Related Macular Degeneration (AMD), Retinitis Pigmentosa (RP), and Stargardt disease. To date there are no effective treatments. Stem cell therapy has been viewed as a very exciting potential avenue that may allow the replacement or repair of these damaged retinal cells.
The study conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia compared the results of transplanted retinal precursor cells with and without the addition of AAGP™. The cells treated with AAGP™ showed an improvement on cell survivability and viability compared to the untreated cells. Ongoing testing is now being conducted to determine if these transplanted cells are fully functioning.
The results of these tests have serious implications for the treatment of other diseases that may benefit from stem cell transplant such as spinal cord injury and the repair of brain damage from stroke. The Company will be exploring the potential of these protocols and procedures using AAGP™ on brain damage caused by ischemic stroke in the coming months.
About ProtoKinetix, Incorporated
ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance both engraftment and protection of transplanted cells used in regenerative medicine.
To subscribe to e-mail updates please follow the following link: Protokinetix.com
Cautionary Note Regarding Forward-Looking Statements
The information discussed in this press release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements, other than statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,” “achievable,” “anticipate,” “will,” “continue,” “potential,” “should,” “could,” and similar terms and phrases. Although we believe that the expectations reflected in these forward looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not be considered to be) guarantees of future performance. Among these risks are those set forth in a Form 10-K filed on February 21, 2017. It is important that each person reviewing this release understand the significant risks attendant to the operations of ProtoKinetix. ProtoKinetix disclaims any obligation to update any forward-looking statement made here.